Northland Securities Begins Coverage on Nephros (NASDAQ:NEPH)

Investment analysts at Northland Securities initiated coverage on shares of Nephros (NASDAQ:NEPH) in a research note issued on Friday, MarketBeat Ratings reports. The brokerage set a “market perform” rating and a $4.00 price target on the stock. Northland Securities’ price objective would indicate a potential upside of 5.82% from the company’s current price.

Separately, Weiss Ratings upgraded shares of Nephros from a “hold (c-)” rating to a “hold (c)” rating in a report on Thursday, June 18th. One analyst has rated the stock with a Buy rating and two have given a Hold rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $5.00.

Nephros Stock Up 0.5%

NASDAQ:NEPH opened at $3.78 on Friday. The business’s 50-day moving average price is $3.45 and its 200 day moving average price is $3.65. The firm has a market cap of $41.05 million, a P/E ratio of 54.01 and a beta of 1.49. Nephros has a 52-week low of $2.66 and a 52-week high of $6.42.

Nephros (NASDAQ:NEPH) last issued its quarterly earnings results on Thursday, May 7th. The company reported $0.01 EPS for the quarter, hitting the consensus estimate of $0.01. Nephros had a net margin of 4.06% and a return on equity of 7.66%. The firm had revenue of $5.21 million for the quarter, compared to analysts’ expectations of $5.02 million.

Hedge Funds Weigh In On Nephros

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Geode Capital Management LLC increased its stake in Nephros by 3.2% in the 2nd quarter. Geode Capital Management LLC now owns 93,187 shares of the company’s stock worth $381,000 after purchasing an additional 2,898 shares in the last quarter. Topline Capital Management LLC lifted its stake in Nephros by 13.1% during the second quarter. Topline Capital Management LLC now owns 477,449 shares of the company’s stock valued at $1,953,000 after buying an additional 55,360 shares in the last quarter. Dimensional Fund Advisors LP purchased a new stake in Nephros during the third quarter valued at about $64,000. Citadel Advisors LLC boosted its holdings in shares of Nephros by 39.2% in the third quarter. Citadel Advisors LLC now owns 16,545 shares of the company’s stock worth $78,000 after buying an additional 4,655 shares during the period. Finally, Navellier & Associates Inc. acquired a new position in shares of Nephros in the fourth quarter worth about $133,000. Institutional investors and hedge funds own 41.10% of the company’s stock.

Nephros Company Profile

Nephros, Inc is a development-stage company specializing in advanced water filtration and purification technologies for medical, laboratory, industrial and defense applications. The company’s core offering centers on proprietary hollow fiber ultrafilters designed to remove bacteria, viruses, endotoxins and particulates from water streams. These ultrafilters are used in hemodialysis systems to protect patient treatment, in pharmaceutical and laboratory environments to ensure water quality and in critical field-deployable units for military and emergency response.

The company’s product portfolio includes standalone filtration cartridges for point-of-use and point-of-entry installations in dialysis clinics and hospitals, as well as bench-top and portable water purification systems.